Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANFNASDAQ:CMNDOTCMKTS:EMMANASDAQ:INM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$1.07-0.9%$1.14$0.98▼$4.69$3.79M1.12237,340 shs38,950 shsCMNDClearmind Medicine$0.86+0.3%$0.97$0.80▼$2.30$3.66M0.91860,940 shs134,211 shsEMMAEmmaus Life Sciences$0.02$0.02$0.00▼$0.10$1.09M8.1139,615 shs5,000 shsINMInMed Pharmaceuticals$2.53-5.9%$2.79$1.72▼$15.70$3.05M0.17554,105 shs155,028 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma-0.93%-2.28%+3.38%-34.36%-65.92%CMNDClearmind Medicine+0.32%-9.46%-11.45%-24.65%-21.19%EMMAEmmaus Life Sciences0.00%+3.66%+41.67%-37.96%-81.48%INMInMed Pharmaceuticals-5.95%-11.85%-24.70%-10.28%-47.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCANFCan-Fite BioPharma3.1597 of 5 stars3.75.00.00.02.20.01.3CMNDClearmind Medicine1.2247 of 5 stars0.05.00.00.02.81.70.0EMMAEmmaus Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AINMInMed Pharmaceuticals0.7897 of 5 stars0.04.00.00.02.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.33Buy$14.001,208.41% UpsideCMNDClearmind Medicine 0.00N/AN/AN/AEMMAEmmaus Life Sciences 0.00N/AN/AN/AINMInMed Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EMMA, CMND, INM, and CANF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$674K5.62N/AN/A$1.76 per share0.61CMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/AEMMAEmmaus Life Sciences$29.60M0.04N/AN/AN/A∞INMInMed Pharmaceuticals$4.92M0.62N/AN/A$5.12 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ACMNDClearmind Medicine-$5.26M-$1.22N/A∞N/AN/A-129.21%-61.15%N/AEMMAEmmaus Life Sciences-$3.73M-$0.11N/A∞N/A-17.11%N/A-12.66%N/AINMInMed Pharmaceuticals-$7.68M-$12.09N/A∞N/A-163.75%-90.74%-71.70%N/ALatest EMMA, CMND, INM, and CANF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q2 2025CMNDClearmind MedicineN/A-$0.16N/A-$0.16N/AN/A5/15/2025Q1 2025EMMAEmmaus Life SciencesN/A-$0.04N/A-$0.04N/AN/A5/12/2025Q3 2025INMInMed PharmaceuticalsN/A-$1.94N/A-$1.94N/A$1.26 million4/14/2025Q4 2024EMMAEmmaus Life SciencesN/A-$0.03N/A-$0.03N/A$3.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/AEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/ACMNDClearmind Medicine0.011.721.72EMMAEmmaus Life SciencesN/A0.140.12INMInMed Pharmaceuticals0.093.052.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%CMNDClearmind Medicine96.05%EMMAEmmaus Life Sciences7.42%INMInMed Pharmaceuticals20.12%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%CMNDClearmind MedicineN/AEMMAEmmaus Life Sciences35.00%INMInMed Pharmaceuticals1.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableEMMAEmmaus Life Sciences6063.87 million41.51 millionNot OptionableINMInMed Pharmaceuticals101.21 million711,000Not OptionableEMMA, CMND, INM, and CANF HeadlinesRecent News About These CompaniesInMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPAJune 13 at 4:30 PM | newsfilecorp.comBest Cannabis Stocks To Follow Now - June 2ndJune 5, 2025 | americanbankingnews.comNew CB1 and CB2 receptor modulators disclosed in Inmed patentMay 31, 2025 | bioworld.comInMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 12, 2025 | newsfilecorp.comInMed Pharmaceuticals Board Reshuffle After Director ResignationFebruary 14, 2025 | tipranks.comInMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024)February 14, 2025 | finance.yahoo.comInMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business UpdateFebruary 12, 2025 | newsfilecorp.comInMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business UpdateFebruary 12, 2025 | newsfilecorp.comInMed Pharmaceuticals: InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular DegenerationFebruary 3, 2025 | finanznachrichten.deInMed advances AMD treatment with promising IVT drug formulationFebruary 3, 2025 | msn.comInMed Pharmaceuticals announces INM-089 IVT formulation as drug candidateFebruary 3, 2025 | markets.businessinsider.comInMed Advances INM-089 for Dry AMD Treatment with New Intravitreal FormulationFebruary 3, 2025 | tipranks.comInMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular DegenerationFebruary 3, 2025 | newsfilecorp.comInMed announces ‘positive’ results from in vivo preclinical Alzheimer’s studyJanuary 22, 2025 | markets.businessinsider.comInMed Pharmaceuticals secures international patentJanuary 22, 2025 | msn.comInMed Pharmaceuticals Announces Granting of Patent for Novel CompoundsJanuary 22, 2025 | newsfilecorp.comInMed Shares Rise, Study Indicates Alzheimer's Drug Could Lower NeuroinflammationJanuary 21, 2025 | marketwatch.comInMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease StudyJanuary 21, 2025 | newsfilecorp.comInMed Announces Results of 2024 Annual General MeetingDecember 18, 2024 | newsfilecorp.comInMed Enters Into Standby Equity Purchase AgreementDecember 17, 2024 | newsfilecorp.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEMMA, CMND, INM, and CANF Company DescriptionsCan-Fite BioPharma NYSE:CANF$1.07 -0.01 (-0.93%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.07 0.00 (0.00%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Clearmind Medicine NASDAQ:CMND$0.86 +0.00 (+0.32%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.84 -0.02 (-2.21%) As of 06/13/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Emmaus Life Sciences OTCMKTS:EMMA$0.02 0.00 (0.00%) As of 06/13/2025 01:08 PM EasternEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.InMed Pharmaceuticals NASDAQ:INM$2.53 -0.16 (-5.95%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.44 -0.09 (-3.75%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
